SCHEDULE 13G/A: Armistice Capital and Steven Boyd Maintain 9.28% Stake in Supernus Pharmaceuticals
Beneficial Ownership Report
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, confirming their beneficial ownership of 9.28% of Supernus Pharmaceuticals, Inc.'s common stock as of March 31, 2025.
Summary
- Armistice Capital, LLC and Steven Boyd (the "Reporting Persons") collectively beneficially own 5,196,000 shares of Supernus Pharmaceuticals, Inc. common stock.
- This ownership represents 9.28% of the Issuer's total outstanding common stock.
- The percentage is calculated based on 55,989,623 shares of Supernus Pharmaceuticals, Inc. common stock outstanding as of April 29, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on May 6, 2025.
- Armistice Capital, LLC, acting as the investment manager, and Steven Boyd, as its managing member, exercise shared voting and dispositive power over these 5,196,000 shares.
- This filing is an Amendment No. 7 to a Schedule 13G, indicating an update to a previously reported beneficial ownership position.
Sentiment
Score: 5
Explanation: Neutral. This is a factual disclosure of beneficial ownership, not a performance report or strategic announcement. The maintenance of a significant stake by an institutional investor could be seen as a neutral to slightly positive signal, but the document itself is purely informational.
Future Outlook
This document is a beneficial ownership report and does not contain forward-looking statements or guidance from the company or the reporting persons regarding the company's future performance.
Industry Context
This filing is a routine disclosure of a significant ownership stake by an institutional investor in a pharmaceutical company. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2025-03-31 | Date of event which requires the filing of this statement. |
| 2025-04-29 | Date as of which the number of outstanding shares (55,989,623) was reported by the Issuer in its Form 10-Q. |
| 2025-05-06 | Date the Issuer's Form 10-Q, reporting outstanding shares, was filed with the SEC. |
| 2025-05-15 | Date of signing and filing of this Schedule 13G/A. |
Keywords
Supernus Pharmaceuticals, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Pharmaceuticals, Institutional Investor, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.